These results (as shown) are by far best in class for an immunotherapy. If we account for the fact that "nine patients were not evaluable for target lesion response assessment by CT scan due to early disease progression or study discontinuation" (4 NSCLC & 5 bladder cancer patients) then the rates drop back to be roughly similar to the IDO/anti-PD-1 combo numbers at around 30% objective response rates.
Of course, T-Vec (engineered herpes virus) cannot be used intravenously against these cancer types so Cavatak is the best performing oncolytic virus in these indications.
GLTAH
VLA Price at posting:
78.0¢ Sentiment: Buy Disclosure: Held
